While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.61 which represents a slight increase of $1.69 or 14.18% from the prior close of $11.92. The stock opened at $11.87 and touched a ...

Novavax Inc (NVAX) stock saw a decline, ending the day at $11.92 which represents a decrease of $-0.37 or -3.01% from the prior close of $12.29. The stock opened at $11.75 and touched a low of $11.09 ...

However, Novavax has remained a notable player in this field. The biotech recently said that its updated vaccine received EUA ...

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know.

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

I'd like to thank you all for joining us for Novavax Corporate presentation certainly for Baird ... Before I go into too much on the Company overview, my goodness, just amazing transformation of this ...

Welcome to the 26th Annual H.C. Wainwright Global Investment Conference. Our next company presenting are -- that we're having a chat today is Novavax, company that by now, hopefully, all of you know ...

Novavax Inc. closed $11.08 short of its 52-week high ($23.86), which the company achieved on June 6th.